Hong Kong University of Technology, two oral antiviral drugs for the new crown can effectively reduce the amount of virus and reduce the mortality rate.
Research from the Hong Kong University School of Medicine found that mild to moderate patients hospitalized with the new coronavirus can effectively reduce the amount of virus and reduce the mortality rate after using two oral antiviral drugs.
research team said that the hospital analyzed the data of hospitalized patients who had been diagnosed with the new coronavirus in Hong Kong from February 26 to April 26 this year. Among the approximately 40,700 patients, the team selected about 2,700 patients suitable for taking oral antiviral drugs to participate in the study, and divided the patients into two groups, patients taking Molnupiravir and control group respectively; the other group was patients taking Paxlovid and related control group patients.
research team pointed out that the results showed that patients with mild to moderate new coronary , using monapiravir and Parksloved in the early stages of the disease, can reduce the risk of death by about 50% and 66%, respectively, and the condition worsens by about 40%; the reduction of the virus volume by nearly 40%. However, in patients with moderate to severe hospitalization, no clinical benefits were found after using monapiravir.
research team believes that this study on patients hospitalized in COVID-19 who do not require oxygen treatment in the early stage reveals that early use of oral antiviral drugs can significantly reduce the risk of death and reduce the amount of virus more quickly, proving the effectiveness of taking these drugs.
